Clinical Trials in Uzbekistan

There are about 17 clinical studies being (or have been) conducted in Uzbekistan.
The country of the clinical trial is determined by the location of where the clinical research is being studied.
Most studies are often held in multiple locations & countries.

This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion
("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex
therapy of pneumonia. Half of participants will receive Rheosorbilact® in complex therapy,
while the other half will receive Ringer's Lactate in complex therapy.

This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion
("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex
therapy of peritonitis. Half of participants will receive Rheosorbilact® in complex therapy,
while the other half will receive Ringer's Lactate in complex therapy.

This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion
("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex
therapy of sepsis. Half of participants will receive Rheosorbilact® in complex therapy, while
the other half will receive Ringer's Lactate in complex therapy.

Pityriasis alba (PA) is a common, benign skin disorder occurring predominantly in children
and adolescents. It is characterized by ill-defined hypopigmented macules and patches, round
or oval in shape. They are most commonly located on the face (especially the cheeks), arms,
and upper trunk; and they are more noticeable in people with darker skin types. Sun exposure
accentuates the lesions. Patients and their parents are often anxious about the cosmetic
appearance of the lesions. PA is not seasonal, although peeling may be worse in the winter
(as a result of dry air in homes) and lesions may be more obvious in the spring and summer
(as a result of sun exposure and darkening of the surrounding skin).No specific cause of PA
has been identified. It is not contagious, and no infectious etiology has been reported. It
is most common in individuals with a history of atopy, although it may occur in nonatopic
individuals.
In the present study, we will investigate the role of serum vitamin D levels and serum total
IgE levels with development and course of PA. Plasma levels of 25(OH) vitamin D and Total
serum immunoglobulin E will be determined by using ELISA technique.

QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY
1. Will the new risk group stratification (especially of T-ALL) to improve overall and
event-free survival?
2. Will the new protocol is effective and feasible in patients older than 15 years, and
especially in young adults?
3. Whether the intermittent dexamethasone administration in induction will result in a
decrease in toxicity and mortality without loss of efficacy?
4. Whether the methylprednisolone administration as basic glucocorticoids during induction,
consolidation and maintenance therapy will lead to decrease of severe infections and
early mortality rate, improve survival and therapy compliance in adolescents and young
adults with B-precursor ALL?
5. Whether the administration of Bortezomib in patients with B-precursor ALL with initial
WBC≥100,000/µl will improve treatment outcome?
6. Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL patients
and two-phase induction in intermediate-risk T-ALL patients will reduce relapse rate and
improve survival?

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have
progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ),
Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive
should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with
pembrolizumab.

The purpose of this study is to obtain additional data on efficacy and safety of 12-week
course of therapy with Anaferon for children for prevention of influenza and other acute
respiratory viral infections in children during the peaks of seasonal morbidity.
Primary objectives of the study:
1. To assess duration of the period from the first dose of the drug until manifestation of
the symptoms of influenza or another acute respiratory viral infection (ARVI) in two
groups of subjects receiving preventive therapy with the study drug (Anaferon for
children) or Placebo.
2. To compare duration of periods from the first dose of the drug until manifestation of
the symptoms of influenza or another ARVI in two groups of subjects (Anaferon for
children and Placebo).
3. Based on the comparison of duration of periods from the first dose of the drug until
manifestation of the symptoms of the disease in these two groups, to assess efficacy of
Anaferon for children for prevention of influenza and other ARVI in children during the
peaks of seasonal morbidity and demonstrate superiority of the study drug over placebo.
Additional study objectives:
1. To assess and compare percentage of children not falling with influenza or another ARVI
in the two groups during 4-, 8- and 12-week course of preventive therapy.
2. To assess and compare percentage of children in the two groups with the symptoms of
respiratory or ear-nose-throat bacterial infections requiring antibacterial therapy
within 12-week preventive therapy.
3. To assess and compare percentage of children hospitalized with influenza/ARVI or their
complications in the two groups within 12-week preventive therapy.
4. Based on collection and analysis of adverse events during the therapy, to obtain
additional information on safety of the study drug

The primary goal of this study is to directly compare repeat doses of sublingual and buccal
routes of 400 mcg misoprostol following mifepristone for second trimester abortion in order
to determine if sublingual route confers an advantage with respect to efficacy and median
time to complete abortion.

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The data & information found on this website is provided “AS IS” from ClinicalTrials.gov.
Neither we, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.